

Remarks

Applicants elect Group I without traverse as defined by Examiner. The claims have been amended accordingly by the Applicant. Claims 29-50 represent subject matter of Group I only, constructed according to 37CFR1.475(b) subparagraph 3, as suggested by the Examiner. The Examiner is therefore requested to examine these claims immediately.

The Applicant reserves the right to pursue subject matter reflected in, for example, the cancelled claims in future applications.

Conclusion


Claims 1-28 have been deleted and new claims 29-50 have been added.

Authorization is hereby given to charge any fees deemed to be due in connection with this Amendment and Response To Restriction Requirement to Deposit Account no. 50-0912.

Respectfully submitted,

KUMAR et al.

By:



George E. Heibel
Reg. No. 42,648

Date: April 12, 2007

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5334
Fax: (609) 514-9779